How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?
| العنوان: | How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection? |
|---|---|
| المؤلفون: | Assaf Mizrahi, Alban Le Monnier, Najoua El Helali, Benoit Pilmis, Céline Mory |
| المصدر: | European Journal of Clinical Microbiology & Infectious Diseases. 40:1393-1397 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Continuous infusion, 030106 microbiology, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Intermittent Infusion, Internal medicine, polycyclic compounds, Medicine, 030212 general & internal medicine, Cefoxitin, Prospective cohort study, PK/PD models, Extended infusion, biology, business.industry, General Medicine, bacterial infections and mycoses, biology.organism_classification, Enterobacteriaceae, Infectious Diseases, Plasma concentration, business, medicine.drug |
| الوصف: | Pharmacological and clinical data regarding cefoxitin for the treatment of ESBL-producing Enterobacteriaceae-related infections are limited. We performed a multicentric prospective cohort study to evaluate continuous/prolonged, or intermittent infusion of cefoxitin. We assessed the plasma concentration as a function of the duration of infusion and then performed a simulation of the percentage of patients who would reach the PK/PD targets, set at 100% ƒT> MIC or 100% ƒT>4 MIC. Eighty-one patients were included. All patients were treated with 6 gr./day. MICs to cefoxitin ranged from 0.5 to 64 mg/L. Sixteen (19.7%) patients were infected with strains with cefoxitin MICs ≥ 8 mg/L. In all patients infected with strains with MICs ≤ 6 mg/L, PK/PD objectives (100% ƒT> MIC) were achieved with prolonged or continuous infusion. In contrast, when MICs were 8 mg/L only, continuous infusion was sufficient to achieve the PK/PD objectives (100% ƒT> MIC). Extended infusion of cefoxitin is necessary for the treatment of non-UTI ESBL-related infections. |
| تدمد: | 1435-4373 0934-9723 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::20ce179d3590639d2e34c2191ffbd906Test https://doi.org/10.1007/s10096-021-04165-xTest |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........20ce179d3590639d2e34c2191ffbd906 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14354373 09349723 |
|---|